TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Lecanemab may be safe and effective for treating early-stage Alzheimer’s disease within a small community of older adults, ...

Long-term treatment with lecanemab shows slowed progression of early Alzheimer’s disease, according to data presented at the ...

BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai presented the latest findings on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC), held in Toronto, ...

Eisai has presented new clinical data showing that patients with early Alzheimer’s disease continue to benefit from four years of treatment with Leqembi (lecanemab). Findings were shared at the ...

Patients could have four more years of good health on the new drug while trial users have seen cognitive improvements too ...

An Alzheimer’s “wonder drug” can delay the progression of the disease by four years, according to a new study. Researchers ...

Single mother Erin Kelly received a life-changing diagnosis in June. But the 29-year-old from Eagleby, Queensland, has known ...

Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...